Milton

Researchers are evaluating ivonescimab as a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors show high PD-L1 expression. This phase 3 randomized, double-blinded study compares ivonescimab with pembrolizumab to assess overall survival and progression-free survival in this patient group. Participants will receive either ivonescimab or pembrolizumab as intravenous injections. The study is designed to monitor these treatments over time to determine which may provide better outcomes in controlling metastatic NSCLC in patients with high PD-L1 levels. The study includes patients with measurable non-brain lesions and no prior systemic treatment for metastatic NSCLC. During the trial, patients will be closely followed for up to approximately 36 months to measure overall survival and progression-free survival. Researchers will assess the safety and effectiveness of the treatments through regular evaluations, including monitoring for disease progression and survival status. This long-term follow-up ensures comprehensive understanding of treatment impact over time.

Researchers are evaluating the long-term stability of the Glide Control System, a new prosthesis control strategy, for people with upper limb amputations either above or below the elbow. The study aims to compare the Glide system against the Pattern Recognition-based myoelectric control to determine if Glide reduces the burden of use for patients and their clinical care teams. The goal is to improve clinical knowledge to better guide prosthesis prescriptions and rehabilitation processes. Participants will use either the Glide Control System or a Pattern Recognition System. Glide uses signals from 2 to 8 muscle sensors to move a cursor on a map that controls different prosthetic movements, while Pattern Recognition uses machine learning to interpret natural muscle patterns for prosthetic control. The study treatment period lasts 168 days from the time the prosthesis is delivered. During the study, participants will be monitored weekly to measure the average daily number of control adjustment sessions and the number of follow-up clinical interventions required. These assessments help evaluate how stable and user-friendly each control system is over time. The study includes regular clinical evaluations and is designed for adults aged 18 and older with a healed upper limb amputation and no prior use of these control systems.